Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

MAXZIDE-25

&times

Overview

What is MAXZIDE-25?

MAXZIDE (triamterene and hydrochlorothiazide) combines triamterene, a potassium-conserving diuretic, with the natriuretic agent, hydrochlorothiazide.

Each MAXZIDE tablet contains:

Triamterene, USP ............................................................................... 75 mgHydrochlorothiazide, USP .................................................................. 50 mg

Each MAXZIDE-25 MG tablet contains:

Triamterene, USP ................................................................................ 37.5 mgHydrochlorothiazide, USP ..................................................................  25 mg

MAXZIDE and MAXZIDE-25 MG tablets for oral administration contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, D&C Yellow No. 10 Aluminum Lake, magnesium stearate, microcrystalline cellulose, powdered cellulose and sodium lauryl sulfate. MAXZIDE-25 MG tablets also contain FD&C Blue No. 1 Aluminum Lake.

Triamterene is 2,4,7-triamino-6-phenylpteridine. Triamterene is practically insoluble in water, benzene, chloroform, ether and dilute alkali hydroxides. It is soluble in formic acid and sparingly soluble in methoxyethanol. Triamterene is very slightly soluble in acetic acid, alcohol and dilute mineral acids. Its molecular weight is 253.27. Its structural formula is:

Hydrochlorothiazide is 6-chloro-3,4-dihydro-2-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is slightly soluble in water and freely soluble in sodium hydroxide solution, n-butylamine and dimethylformamide. It is sparingly soluble in methanol and insoluble in ether, chloroform and dilute mineral acids. Its molecular weight is 297.73. Its structural formula is:



What does MAXZIDE-25 look like?



What are the available doses of MAXZIDE-25?

Sorry No records found.

What should I talk to my health care provider before I take MAXZIDE-25?

Sorry No records found

How should I use MAXZIDE-25?

This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.

MAXZIDE may be used alone or in combination with other antihypertensive drugs, such as beta-blockers. Since MAXZIDE (triamterene and hydrochlorothiazide) may enhance the actions of these drugs, dosage adjustments may be necessary.

The usual dose of MAXZIDE-25 MG is one or two tablets daily, given as a single dose, with appropriate monitoring of serum potassium (see ). The usual dose of MAXZIDE is one tablet daily, with appropriate monitoring of serum potassium (see ). There is no experience with the use of more than one MAXZIDE tablet daily or more than two MAXZIDE-25 MG tablets daily. Clinical experience with the administration of two MAXZIDE-25 MG tablets daily in divided doses (rather than as a single dose) suggests an increased risk of electrolyte imbalance and renal dysfunction.

Patients receiving 50 mg of hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE (triamterene and hydrochlorothiazide) directly. Patients receiving 25 mg hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE-25 MG (37.5 mg triamterene/25 mg hydrochlorothiazide) directly.

In patients requiring hydrochlorothiazide therapy and in whom hypokalemia cannot be risked therapy may be initiated with MAXZIDE-25 MG. If an optimal blood pressure response is not obtained with MAXZIDE-25 MG, the dose should be increased to two MAXZIDE-25 MG tablets daily as a single dose, or one MAXZIDE tablet daily. If blood pressure still is not controlled, another antihypertensive agent may be added (see ).

Clinical studies have shown that patients taking less bioavailable formulations of triamterene and hydrochlorothiazide in daily doses of 25 mg to 50 mg hydrochlorothiazide and 50 mg to 100 mg triamterene may be safely changed to one MAXZIDE-25 MG tablet daily. All patients changed from less bioavailable formulations to MAXZIDE should be monitored clinically and for serum potassium after the transfer.


What interacts with MAXZIDE-25?

Sorry No Records found


What are the warnings of MAXZIDE-25?

Array





If hyperkalemia is suspected, (warning signs include paresthesias, muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia and shock) an electrocardiogram (ECG) should be obtained. However, it is important to monitor serum potassium levels because mild hyperkalemia may not be associated with ECG changes.

If hyperkalemia is present, MAXZIDE (triamterene and hydrochlorothiazide) should be discontinued immediately and a thiazide alone should be substituted. If the serum potassium exceeds 6.5 mEq/liter, more vigorous therapy is required. The clinical situation dictates the procedures to be employed. These include the intravenous administration of calcium chloride solution, sodium bicarbonate solution and/or the oral or parenteral administration of glucose with a rapid-acting insulin preparation. Cationic exchange resins such as sodium polystyrene sulfonate may be orally or rectally administered. Persistent hyperkalemia may require dialysis.

The development of hyperkalemia associated with potassium-sparing diuretics is accentuated in the presence of renal impairment (see ). Patients with mild renal functional impairment should not receive this drug without frequent and continuing monitoring of serum electrolytes. Cumulative drug effects may be observed in patients with impaired renal function. The renal clearances of hydrochlorothiazide and the pharmacologically active metabolite of triamterene, the sulfate ester of hydroxytriamterene, have been shown to be reduced and the plasma levels increased following MAXZIDE (triamterene and hydrochlorothiazide) administration to elderly patients and patients with impaired renal function.

Hyperkalemia has been reported in diabetic patients with the use of potassium-conserving agents even in the absence of apparent renal impairment. Accordingly, MAXZIDE (triamterene and hydrochlorothiazide) should be avoided in diabetic patients. If it is employed, serum electrolytes must be frequently monitored.

Because of the potassium-sparing properties of angiotensin-converting enzyme (ACE) inhibitors, MAXZIDE should be used cautiously, if at all, with these agents (see ).

Metabolic or Respiratory Acidosis

Potassium-conserving therapy should also be avoided in severely ill patients in whom respiratory or metabolic acidosis may occur. Acidosis may be associated with rapid elevations in serum potassium levels. If MAXZIDE is employed, frequent evaluations of acid/base balance and serum electrolytes are necessary.

Acute Myopia and Secondary Angle-Closure Glaucoma

Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.


What are the precautions of MAXZIDE-25?

General

Array



Array

MAXZIDE should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Array

Triamterene has been reported in renal stones in association with other calculus components. MAXZIDE should be used with caution in patients with histories of renal lithiasis.

Array

Triamterene is a weak folic acid antagonist and may contribute to the appearance of megaloblastosis in instances where folic acid stores are decreased. In such patients, periodic blood elevations are recommended.

Array

Hyperuricemia may occur or acute gout may be precipitated in certain patients receiving thiazide therapy.

Metabolic and Endocrine Effects

The thiazides may decrease serum PBI levels without signs of thyroid disturbance.

Calcium excretion is decreased by thiazides. Pathological changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been observed in a few patients on prolonged thiazide therapy. The common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen. Thiazides should be discontinued before carrying out tests for parathyroid function.

Insulin requirements in diabetic patients may be increased, decreased or unchanged. Diabetes mellitus which has been latent may become manifest during thiazide administration.

Hypersensitivity

Sensitivity reactions to thiazides may occur in patients with or without a history of allergy or bronchial asthma.

Possible exacerbation or activation of systemic lupus erythematosus by thiazides has been reported.

Drug Interactions

Thiazides may add to or potentiate the action of other antihypertensive drugs.

The thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Thiazides have also been shown to increase the responsiveness to tubocurarine.

Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. Refer to the package insert on lithium before use of such concomitant therapy.

Acute renal failure has been reported in a few patients receiving indomethacin and formulations containing triamterene and hydrochlorothiazide. Caution is therefore advised when administering non-steroidal anti-inflammatory agents with MAXZIDE (triamterene and hydrochlorothiazide).

Potassium-sparing agents should be used very cautiously, if at all, in conjunction with angiotensin-converting enzyme (ACE) inhibitors due to a greatly increased risk of hyperkalemia. Serum potassium should be monitored frequently.

Drug/Laboratory Test Interactions

Triamterene and quinidine have similar fluorescence spectra; thus MAXZIDE (triamterene and hydrochlorothiazide) may interfere with the measurement of quinidine.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Array

Long-term studies with MAXZIDE, the triamterene/hydrochlorothiazide combination, have not been conducted.

Array

Studies of the mutagenic potential of MAXZIDE, the triamterene/hydrochlorothiazide combination, have not been performed.

Array

Studies of the effects of MAXZIDE, the triamterene/hydrochlorothiazide combination, or of triamterene alone on animal reproductive function have not been conducted.

Pregnancy: Category C

Array

Array

Thiazides and triamterene have been shown to cross the placental barrier and appear in cord blood. The use of thiazides and triamterene in pregnant women requires that the anticipated benefits be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, pancreatitis, thrombocytopenia, and possibly other adverse reactions that have occurred in the adult.

Nursing Mothers

Thiazides and triamterene in combination have not been studied in nursing mothers. Triamterene appears in animal milk and this may occur in humans. Thiazides are excreted in human breast milk. If use of the combination drug product is deemed essential, the patient should stop nursing.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.


What are the side effects of MAXZIDE-25?

Side effects observed in association with the use of MAXZIDE, other combination products containing triamterene/hydrochlorothiazide, and products containing triamterene or hydrochlorothiazide include the following:

Gastrointestinal:

Central Nervous System:

Cardiovascular:

Renal:

Hematologic:

Ophthalmic:

Hypersensitivity:

Other:

Whenever adverse reactions are moderate to severe, therapy should be reduced or withdrawn.

Altered Laboratory Findings:

Serum Electrolytes:

Creatinine, Blood Urea Nitrogen:

Glucose:

Serum Uric Acid, PBI and Calcium:

Other:


What should I look out for while using MAXZIDE-25?


What might happen if I take too much MAXZIDE-25?

No specific data are available regarding MAXZIDE (triamterene and hydrochlorothiazide) overdosage in humans and no specific antidote is available.

Fluid and electrolyte imbalances are the most important concern. Excessive doses of the triamterene component may elicit hyperkalemia, dehydration, nausea, vomiting and weakness and possibly hypotension. Overdosing with hydrochlorothiazide has been associated with hypokalemia, hypochloremia, hyponatremia, dehydration, lethargy (may progress to coma) and gastrointestinal irritation. Treatment is symptomatic and supportive. Therapy with MAXZIDE (triamterene and hydrochlorothiazide) should be discontinued. Induce emesis or institute gastric lavage. Monitor serum electrolyte levels and fluid balance. Institute supportive measures as required to maintain hydration, electrolyte balance, respiratory, cardiovascular and renal function.


How should I store and handle MAXZIDE-25?

Storage and HandlingStore unopened bottle in refrigerator between 2° to 8°C (36° to 46°F). After opening, store bottle in use in an upright position at 20° to 25°C (68° to 77°F). Excursions permitted to 15° to 30°C (59° to 86°F). Discard the bottle after 30 doses have been used.Storage and HandlingStore unopened bottle in refrigerator between 2° to 8°C (36° to 46°F). After opening, store bottle in use in an upright position at 20° to 25°C (68° to 77°F). Excursions permitted to 15° to 30°C (59° to 86°F). Discard the bottle after 30 doses have been used.MAXZIDE tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:NDC 0378-0460-01bottles of 100 tabletsMAXZIDE-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows: NDC 0378-0464-01bottles of 100 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Protect from light. Dispense in a tight, light-resistant, child-resistant container.Mylan Pharmaceuticals Inc. REVISED SEPTEMBER 2015BKMAX:R10MAXZIDE tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:NDC 0378-0460-01bottles of 100 tabletsMAXZIDE-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows: NDC 0378-0464-01bottles of 100 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Protect from light. Dispense in a tight, light-resistant, child-resistant container.Mylan Pharmaceuticals Inc. REVISED SEPTEMBER 2015BKMAX:R10MAXZIDE tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:NDC 0378-0460-01bottles of 100 tabletsMAXZIDE-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows: NDC 0378-0464-01bottles of 100 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Protect from light. Dispense in a tight, light-resistant, child-resistant container.Mylan Pharmaceuticals Inc. REVISED SEPTEMBER 2015BKMAX:R10MAXZIDE tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:NDC 0378-0460-01bottles of 100 tabletsMAXZIDE-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows: NDC 0378-0464-01bottles of 100 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Protect from light. Dispense in a tight, light-resistant, child-resistant container.Mylan Pharmaceuticals Inc. REVISED SEPTEMBER 2015BKMAX:R10MAXZIDE tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:NDC 0378-0460-01bottles of 100 tabletsMAXZIDE-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows: NDC 0378-0464-01bottles of 100 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Protect from light. Dispense in a tight, light-resistant, child-resistant container.Mylan Pharmaceuticals Inc. REVISED SEPTEMBER 2015BKMAX:R10MAXZIDE tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:NDC 0378-0460-01bottles of 100 tabletsMAXZIDE-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows: NDC 0378-0464-01bottles of 100 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Protect from light. Dispense in a tight, light-resistant, child-resistant container.Mylan Pharmaceuticals Inc. REVISED SEPTEMBER 2015BKMAX:R10MAXZIDE tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:NDC 0378-0460-01bottles of 100 tabletsMAXZIDE-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows: NDC 0378-0464-01bottles of 100 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Protect from light. Dispense in a tight, light-resistant, child-resistant container.Mylan Pharmaceuticals Inc. REVISED SEPTEMBER 2015BKMAX:R10MAXZIDE tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:NDC 0378-0460-01bottles of 100 tabletsMAXZIDE-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows: NDC 0378-0464-01bottles of 100 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Protect from light. Dispense in a tight, light-resistant, child-resistant container.Mylan Pharmaceuticals Inc. REVISED SEPTEMBER 2015BKMAX:R10MAXZIDE tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:NDC 0378-0460-01bottles of 100 tabletsMAXZIDE-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with to the left of the score and to the right of the score on one side of the tablet and on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows: NDC 0378-0464-01bottles of 100 tabletsStore at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]Protect from light. Dispense in a tight, light-resistant, child-resistant container.Mylan Pharmaceuticals Inc. REVISED SEPTEMBER 2015BKMAX:R10


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Hydrochlorothiazide is a diuretic and antihypertensive agent. It blocks the renal tubular absorption of sodium and chloride ions. This natriuresis and diuresis is accompanied by a secondary loss of potassium and bicarbonate. Onset of hydrochlorothiazide’s diuretic effect occurs within 2 hours and the peak action takes place in 4 hours. Diuretic activity persists for approximately 6 to 12 hours.

The exact mechanism of hydrochlorothiazide’s antihypertensive action is not known although it may relate to the excretion and redistribution of body sodium. Hydrochlorothiazide does not affect normal blood pressure.

Following oral administration, peak hydrochlorothiazide plasma levels are attained in approximately 2 hours. It is excreted rapidly and unchanged in the urine.

Well controlled studies have demonstrated that doses of hydrochlorothiazide as low as 25 mg given once daily are effective in treating hypertension, but the dose-response has not been clearly established.

Non-Clinical Toxicology
Thiazides may add to or potentiate the action of other antihypertensive drugs.

The thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Thiazides have also been shown to increase the responsiveness to tubocurarine.

Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. Refer to the package insert on lithium before use of such concomitant therapy.

Acute renal failure has been reported in a few patients receiving indomethacin and formulations containing triamterene and hydrochlorothiazide. Caution is therefore advised when administering non-steroidal anti-inflammatory agents with MAXZIDE (triamterene and hydrochlorothiazide).

Potassium-sparing agents should be used very cautiously, if at all, in conjunction with angiotensin-converting enzyme (ACE) inhibitors due to a greatly increased risk of hyperkalemia. Serum potassium should be monitored frequently.

Side effects observed in association with the use of MAXZIDE, other combination products containing triamterene/hydrochlorothiazide, and products containing triamterene or hydrochlorothiazide include the following:

Gastrointestinal:

Central Nervous System:

Cardiovascular:

Renal:

Hematologic:

Ophthalmic:

Hypersensitivity:

Other:

Whenever adverse reactions are moderate to severe, therapy should be reduced or withdrawn.

Altered Laboratory Findings:

Serum Electrolytes:

Creatinine, Blood Urea Nitrogen:

Glucose:

Serum Uric Acid, PBI and Calcium:

Other:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).